04
Mar

With Baxter’s bioscience division getting ready to spin out into an independent operation with an R&D base in Boston, the company has struck a deal to buy out SuppreMol for $225 million in cash. Baxter is planning to continue operating the biotech at its Munich facility, where SuppreMol has been working on new drugs for autoimmune diseases.

…read more

Source: As split looms, Baxter bags autoimmune biotech SuppreMol for $225M

    

0 No comments